NCT04671303 2025-05-11To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung CancerCancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2 Completed36 enrolled